DKK1 and Miyoshi myopathy: A study of newly diagnosed MM patients used serial measurements of serum DKK-1 and sclerostin to correlate with disease stage and bone lesion burden, showing marked declines in these markers after effective therapy, thus reinforcing their utility in monitoring disease activity and therapeutic response [120,127].